News & Events

hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Wayde McMillan Wayde McMillan Executive Vice President and Chief Financial Officer (Principal Financial Officer) Dated: May 5, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 20, 2026, Mary Wilcox informed Solventum Corporation (the “Company”) of her intent to retire and resign from her position as Chief Accounting Officer of the Company following a search for and appointment of her successor.

hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: February 26, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 21, 2025, Solventum Corporation (the “Company”) announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer of the Company, effective as of November 10, 2025. Ms. Knight will oversee all global commercial and R&D operations across the Company’s MedSurg, Dental Solutions and Health Infor…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On April 12, 2024, the Board of Directors (the “Board”) of Solventum Corporation (the “Company”) elected Shirley A. Edwards to the Company’s Board, effective April 12, 2024. Ms. Edwards was a Partner at EY (formerly Ernst & Young LLP) from 2002 to 2022, most recently serving as a Global Client Service Partner from 2017 to 2022. Ms. Edwards will join…

Entry into a Material Definitive Agreement. Separation-Related Agreements On March 31, 2024, Solventum Corporation (“Solventum”) entered into several agreements with 3M Company (“3M”) in connection with the spin-off of 3M’s health care business (the “Separation”) through the pro rata distribution of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum to 3M’s stockholders of record as of the close of business on March 18, 2024 (the “Distribution”…

Material Modifications to Rights of Security Holders The information set forth under

The biographical information for each other executive officer is set forth below. Mary Wilcox, 60, is the Senior Vice President, Controller and Chief Accounting Officer of Solventum. She joined 3M’s healthcare business in December 2023. Prior to joining Solventum, Ms. Wilcox was Vice President, Chief Accounting Officer at Medtronic PLC (“Medtronic”), a healthcare technology company, where she worked for over 30 years in various roles of increasing responsibility. She also served as Assistant…

Regulation FD Disclosure Information Statement Solventum Corporation (“Solventum”), a wholly owned subsidiary of 3M Company (“3M”), previously filed with the U.S. Securities and Exchange Commission a registration statement on Form 10 (as amended, the “Registration Statement”) relating to the planned distribution by 3M of 80.1% of the issued and outstanding shares of common stock, par value $0.01 per share, of Solventum (the “Solventum common stock”) to 3M shareholders. On March 13, 2024, the…